Indian Pharmacopoeia Commission secretary-cum-scientific director Rajeev Singh Raghuvanshi has been recommended to be the next Drugs Controller General of India (DCGI). The Union Public Service Commission (UPSC) has recommended to the government his name as the successor to Dr V G Somani, whose extended tenure will end mid-February, officials said.
The UPSC recommendation has to be approved by the Health Ministry, followed by approval of the Appointments Committee of Cabinet led by Prime Minister Narendra Modi, they said.
Dr Somani, Dr Raghuvanshi and Dr Jai Prakash, senior principal scientific officer at the Indian Pharmacopoeia Commission (IPC), appeared for interviews conducted by the UPSC last week.
“The Union Public Service Commission on the basis of assessment of bio-data of the eligible officers received…and after holding personal talks with them on January 27 recommend Dr Rajeev Singh Raghuvanshi for appointment to the post of Drug Controller (India) by short term contract basis,” according to the UPSC communication to the Health Ministry.
Dr Somani was appointed DCGI for a term of three years on August 14, 2019 and he took charge on August 16.
His tenure was extended twice — on August 16 and November 16 — for three months each.
The DCGI heads the Central Drugs Standard Control Organisation (CDSCO) which is responsible for ensuring quality drugs supply across the country. It also has authority to give approval to new drugs and regulating clinical trials.
He completed his Bachelors and Masters from IIT-BHU (formerly IT-BHU), Varanasi and PhD from the National Institute of Immunology, New Delhi.
After working for seven years at the National Institute of Immunology, he joined leading Indian multinational pharmaceutical company Ranbaxy Laboratories Ltd.
After 12 years at Ranbaxy Laboratories, he moved to Dr Reddy’s Laboratories Ltd, Hyderabad, where he worked for 11 years.
Dr Raghuvanshi’s expertise lies in dosage form design and development, mainly in the domain of pharmaceutical innovation. He has been involved in development of different kind of products such as oral solids, oral liquids, topicals, injections, nasal sprays, auto-injectors, sublingual, mouth dissolve, extended release and delayed release for global markets.
More than 200 products developed by him and his teams are currently being sold in India, US, Europe and emerging markets.
Dr Raghuvanshi has 14 granted US patents along with more than 250 published patent cooperation treaties and Indian patents. He has more than 25 publications in peer reviewed journals and has co-authored six chapters in books.
For his contribution, Dr Reddy’s Labs has twice awarded him with “Dr Reddy’s Excellence Award”.
